Shire PLC (SHPG) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Shire PLC (NASDAQ:SHPG) have received an average rating of “Buy” from the twenty-four brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $211.00.
Several research analysts have commented on the company. FBR & Co restated a “buy” rating and set a $201.00 price objective on shares of Shire PLC in a report on Monday. Piper Jaffray Companies restated a “hold” rating and set a $160.00 price objective on shares of Shire PLC in a report on Friday, October 27th. Cowen and Company set a $225.00 price objective on Shire PLC and gave the stock a “buy” rating in a report on Sunday. Jefferies Group LLC restated a “hold” rating and set a $206.00 price objective (down from $216.00) on shares of Shire PLC in a report on Wednesday, August 9th. Finally, Barclays PLC downgraded Shire PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th.
COPYRIGHT VIOLATION NOTICE: “Shire PLC (SHPG) Given Consensus Recommendation of “Buy” by Brokerages” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/01/shire-plc-shpg-given-consensus-recommendation-of-buy-by-brokerages.html.
Several hedge funds have recently modified their holdings of the company. Inspirion Wealth Advisors LLC lifted its holdings in shares of Shire PLC by 0.4% in the 2nd quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 8 shares during the period. Synovus Financial Corp lifted its holdings in shares of Shire PLC by 0.4% in the 2nd quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock valued at $458,000 after buying an additional 11 shares during the period. Baldwin Investment Management LLC lifted its holdings in shares of Shire PLC by 1.4% in the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 23 shares during the period. Hartford Financial Management Inc. lifted its holdings in shares of Shire PLC by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 32 shares during the period. Finally, Lumbard & Kellner LLC lifted its holdings in shares of Shire PLC by 0.3% in the 2nd quarter. Lumbard & Kellner LLC now owns 18,170 shares of the biopharmaceutical company’s stock valued at $3,003,000 after buying an additional 55 shares during the period. 19.27% of the stock is owned by institutional investors and hedge funds.
Shares of Shire PLC (NASDAQ SHPG) traded down 1.175% during trading on Wednesday, reaching $145.895. The company’s stock had a trading volume of 923,992 shares. Shire PLC has a 12-month low of $137.80 and a 12-month high of $192.64.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, topping the consensus estimate of $3.64 by $0.17. The company had revenue of $3.70 billion for the quarter. Shire PLC had a return on equity of 14.73% and a net margin of 10.95%. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.17 earnings per share. Equities analysts anticipate that Shire PLC will post $14.97 EPS for the current year.
The business also recently disclosed a semiannual dividend, which was paid on Friday, October 20th. Stockholders of record on Friday, September 8th were issued a $0.1527 dividend. The ex-dividend date of this dividend was Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is presently 17.23%.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.